Lmcg Investments LLC Boosts Stock Position in Danaher Co. (NYSE:DHR)

Lmcg Investments LLC boosted its position in shares of Danaher Co. (NYSE:DHRFree Report) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,079 shares of the conglomerate’s stock after purchasing an additional 340 shares during the period. Danaher makes up 1.3% of Lmcg Investments LLC’s holdings, making the stock its 11th biggest holding. Lmcg Investments LLC’s holdings in Danaher were worth $20,376,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. BKM Wealth Management LLC purchased a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the 4th quarter valued at about $29,000. OFI Invest Asset Management acquired a new stake in shares of Danaher in the third quarter valued at approximately $30,000. Rakuten Securities Inc. acquired a new stake in Danaher during the 4th quarter worth $36,000. Finally, Financial Connections Group Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 19,085 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Rainer Blair sold 19,085 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 166,824 shares of company stock worth $41,963,189. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of several analyst reports. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. TD Cowen lifted their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Royal Bank of Canada boosted their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Check Out Our Latest Report on Danaher

Danaher Stock Up 1.6 %

NYSE DHR traded up $4.02 on Wednesday, reaching $263.28. The company had a trading volume of 3,072,598 shares, compared to its average volume of 2,697,800. The firm has a market capitalization of $195.01 billion, a PE ratio of 44.36, a P/E/G ratio of 3.87 and a beta of 0.83. The firm has a 50-day moving average of $248.07 and a 200-day moving average of $235.23. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $264.02.

Danaher (NYSE:DHRGet Free Report) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 EPS. On average, equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.